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Abstract
Background: Tumor metastasis and changes in host immunosurveillance are important components in cancer development.
Tumor cell invasion into the bloodstream is an essential step for systemic metastasis. Currently, the detection of tumor cells in
the circulation is mainly dependent upon the utilization of known epithelial cell markers. However, expression of these
molecules is not limited to cancer patients; healthy people also have a small number of epithelial cells in their circulation. Utilizing
these markers to detect circulating tumor cells (CTCs) cannot adequately explain the mechanisms of tumor cell survival or their
development of metastatic potential in peripheral blood. The immune system can also evolve along with the cancer, actually
promoting or selecting the outgrowth of tumor variants. Unfortunately, both metastasis and immunosurveillance remain
mysterious and are debatable because we have yet to define the molecules that participate in these processes. We are interested
in identifying the existence of expressed genes, or mRNA species, that are specifically associated with circulating cells of cancer-
bearing patients using prostate cancer (PCa) as a model.
Results:  We established two comprehensive subtracted cDNA libraries using a molecular technique called suppression
subtractive hybridization. This technique selectively amplifies transcripts that are specifically expressed in circulating cells of either
PCa patients or healthy men. Following sequencing reaction, we showed that 17 out of 23 (73.9%) sequenced clones did not
match any mRNAs in the GenBank database. This result suggests that genes associated with alterations in circulating cells of
cancer-bearing patients are largely unknown. Semi-quantitative RT-PCR confirmed that two genes are up-regulated in circulating
cells of PCa patients, whereas another two genes are down-regulated in the same patients.
Conclusion: The comprehensive gene expression analysis is capable of identifying differentially expressed genes in circulating
cells of healthy men and PCa patients. We did not attempt to enrich specific cell types in this study because phenotypes of CTCs
and subsets of leukocytes participating in immunosurveillance remain largely unknown. Continuous studies of these differentially
expressed genes will eventually lead us to understand the mechanisms involved in tumor metastasis and immune modulation
during cancer development.
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Background
Metastasis is a sequential, multi-step process in which
tumor cells detach from the primary tumor, migrate
through the basement membrane and extracellular
matrix, and invade the lymphatic and/or blood systems
[1]. This is followed by the establishment of secondary
tumors at distant sites. It has been suggested that tumor
cell invasion into the bloodstream can occur earlier than
the time of primary diagnosis [2]. The ability to detect
occult tumor cells with metastatic potential could have a
substantial clinical impact on the management of cancer
patients. Most, if not all, markers developed to detect
occult tumor cells of epithelium origin in peripheral
blood have been based on the concept that circulating
tumor cells (CTCs) continue to express epithelial cell
markers [3]. Based on this concept, several epithelial cell
markers have been evaluated for detecting disseminated
tumor cells in the blood circulation. Frequently used mol-
ecules include cytokeratins (CKs) 7, 19, and 20 [4-6], car-
cinoembryonic antigen (CEA) [7,8], epidermal growth
factor receptor [9] including HER-2/neu [10], mucin-1
[11],  β-subunit of human chorionic gonadotropin (β-
hCG) [12], and α-fetoprotein [13]. In prostate cancer
(PCa) patients, the expression of prostate specific antigen
(PSA) [14-16], prostate-specific membrane antigen
(PSMA) [17,18], and human glandular kallikrein 2 (hK2)
[19] along with other epithelial cell markers has been
investigated individually or in combination [20] for their
ability to detect CTCs in patients with localized and met-
astatic PCa. This detection strategy involves the amplifica-
tion of target mRNAs species by reverse transcriptase-
polymerase chain reaction (RT-PCR) [21-23]. However,
the use of these markers to detect CTCs fails to explain
mechanisms that regulate tumor cell survival in the circu-
lation and the development of their metastatic capability.
Recent reports have also emphasized that the immune sys-
tem actively participates in cancer formation and develop-
ment. Although this concept of immune response was
formulated more than half a century ago [24], the exist-
ence of cancer "immunosurveillance" is still largely
unknown and debatable because we know very little
about the molecules participating in this event. If cancer
"immunoediting" is present under the concept of cancer
immunosurveillance, we hypothesized that genes
expressed in immune cells participating in this event are
significantly different from their counterparts in healthy
persons.
We also hypothesized that both CTCs and immune cells
need to evolve through their gene expression at stages of
cancer formation and progression. The identified mRNA
species associated with circulating cells of cancer-bearing
patients will serve as independent markers for future
tumor staging and help us understand metastasis and
immunosurveillance. In this study, using PCa as a model,
we applied the suppression suppressive hybridization
(SSH) technique [25] to establish two libraries consisting
of mRNA species that are either present or absent in circu-
lating cells of PCa patients. We sequenced a small number
of clones present in these libraries, and identified that the
majority, 17 out of 23 (73.9%), of the sequenced clones
did not match previously identified mRNA species. From
the sequenced clones, we confirmed that four genes are
differentially expressed in circulating cells of healthy men
and PCa patients using semi-quantitative RT-PCR. Two
mRNA species were identified to be significantly elevated
in PCa patients, and two mRNA species were identified to
be significantly suppressed in PCa patients.
Results and Discussion
Current protocols for detecting CTCs mainly utilize
known epithelial cell markers or other tissue-specific mol-
ecules [26]. However, the presence of these markers in
CTCs does not correlate with their survival in the circula-
tion and their metastatic capability. Furthermore, mole-
cules that participate in the process of
"immunosurveillance" remain poorly understood. In this
report, we used a PCR-based, genome-wide gene expres-
sion analysis named SSH to establish comprehensive,
subtracted cDNA libraries to catalogue mRNA species
either present or absent in circulating cells of PCa patients.
The SSH libraries were constructed from two age- and
race-matched, pooled sample populations, healthy men
and PCa patients. Each pooled sample consisted of 25
individual double-stranded cDNA libraries derived from
circulating cell poly(A)+ RNA of 25 men. We used a PCR-
based method to evaluate the hybridization efficiency.
After two rounds of hybridization, β-actin was amplified
from a subtracted population using a pair of gene-specific
primers located within the very 3' end of Rsa I digested β-
actin. No DNA product was detectable after 40 cycles of
amplification (Figure 1A), whereas the corresponding un-
subtracted library showed the presence of abundant β-
actin. This result demonstrated that β-actin, and possibly
the majority of commonly expressed genes between the
two sample populations, formed heterohybrids, and
could not be amplified using the suppression PCR tech-
nique [25]. To demonstrate that the subtracted cDNA
libraries contain potential differently expressed mRNA
species, the PCR products were electrophoresed on an aga-
rose gel following the second round of PCR. A series of
DNA fragments, ranging from 300 to 1,000 bp in size, rep-
resenting mRNA species specifically expressed in PCa
patients were detected. The various PCR products repre-
sent the Rsa I digested cDNA fragments are shown in Fig-
ure 1B, lane 1. These results indicated that there are
differentially expressed genes present only in the
circulating cells of PCa patients but not healthy men. PCRMolecular Cancer 2005, 4:30 http://www.molecular-cancer.com/content/4/1/30
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products representing genes expressed only in the circulat-
ing cells of healthy men are shown in Figure 1B, lane 2.
To reveal the identities of the cDNA clones, the second
round PCR products from both subtracted libraries were
subcloned into the pCRII TA cloning vector. A total of 23
clones from both subtracted libraries were randomly
selected for sequencing using M13 reverse primer. Identi-
ties of these clones are listed in Table 1. A majority of the
sequenced clones, 17 out of 23 (73.9%), matched to
genomic DNA fragments in the GenBank database, but
not previously identified mRNA species. These results
might reflect that some of these clones were amplified
from rare CTCs in PCa patients and mRNA species reflect-
ing these cells' biology or pathology have not been
identified using traditional cDNA construction and
Evaluation of subtraction efficiency and the presence of potential differentially expressed genes in the subtracted libraries Figure 1
Evaluation of subtraction efficiency and the presence of potential differentially expressed genes in the sub-
tracted libraries. To determine the subtraction efficiency, β-actin was PCR amplified using a primer set located within the 
very 3'-end of Rsa I digested β-actin fragment following the second round of hybridization. PCR products were electro-
phoresed on an agarose gel. No β-actin product was detected after 40 cycles of PCR amplification in a subtracted library, 
whereas β-actin was detected after 25 cycles of amplification in corresponding un-subtracted library (A). To amplify differen-
tially expressed genes in circulating cells of healthy men and PCa patients, two rounds of PCR amplification was performed fol-
lowing hybridization steps described in Materials and Methods. To demonstrate the presence of potential differentially 
expressed genes in the subtracted libraries, the final PCR products were analyzed on a 1.5% agarose gel followed by ethidium 
bromide staining. We detected a series of distinct bands ranging from 300 to 1,000 bp. These DNA fragments represented 
genes that are either present (B, lane 1) or absent (B, lane 2) in circulating cells of PCa patients.
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sequencing. In addition, it is possible that genes identified
from both subtracted libraries may represent previously
un-identified molecules participating in tumor-immune
system interactions [27-30].
Since a portion of the subtracted cDNAs may be false pos-
itive clones [25], we needed to confirm the identified
clones as truly differentially expressed genes in our two
sample populations. We used semi-quantitative RT-PCR
to confirm that the cloned cDNAs are associated with
peripheral blood circulating cells of cancer-bearing
patients. Samples were collected from 12 PCa patients and
8 age- and race-matched healthy men for this analysis. RT-
PCR was performed on individual samples. A total of 20
samples, 8 healthy men and 12 PCa patients, total RNA
was analyzed for selected genes. Four target genes were
selected to be confirmed by RT-PCR. Two genes, PCa-001
and PCa-002, were selected from the library that consists
of mRNA species only present in circulating cells of PCa
patients. PCR primers were designed according to the
Table 1: Identities of selected cDNA clones present in subtracted libraries
Clone I.D. GenBank Accession No. Gene Description
PCa-001* AC026205 Homo sapiens chromosome 3 clone RP11-61I9 map 3p, complete sequence
PCa-002 AC019106 Homo sapiens BAC clone RP11-479L11 from 2, complete sequence
PCa-004 AY341247.1 Homo sapiens integral membrane protein 2B (ITM2B) gene, complete cds
PCa-005 AC104771.4 Homo sapiens BCA clone RP11-1E1 from 4, complete sequence
PCa-006 AC132068 Homo sapiens chromosome 16 clone CTD-2326c4, complete sequence
PCa-007 AK091994 Home sapiens cDNA FLJ34675 fis, clone Liver2001608
PCa-008 AC092910.9 Homo sapiens 3 BAC Rp11-767L7 (Roswell Park Cancer institute human BCA Library)
PCa-009 AC004690.2 Homo sapiens PAC clone RP-630c24 from 7, complete sequence
PCa-010 AC097461 Homo sapiens bCA clone RP11-6P6 from 2, complete sequence
PCa-011 BC047553 Homo sapiens calmodulin 2 mRNA (phosphorylase kinase δ)
PCa-012 AL031274 Homo sapiens chromosome 1q24 (clone RP4-798A17) contains the 3' part of the FMO1 gene and the 
FMO4 gene
PCa-013 AC010369 Homo sapiens chromosome 5 (clone CTC-2048F20)
PCa-014 NG_002397 Homo sapiens major histocompatibility complex, class I, BC (HLA-BC)
PCa-015 BC016320 Homo sapiens cathepsin D (Lysosomal aspartyl protease) mRNA
PCa-016 AC021701 Homo sapiens chromosome 18 (clone RP11-704G7)
Nrml-001** AC004914.1 Homo sapiens PCA clone RP5-88608 from 7, complete sequence
Nrml-002 AK095899.1 Homo sapiens cDNA FLJ38580 fis, clone HCHON2008582, highly similar to ferritin heavy chain
Nrml-003 AC006083 Homo sapiens chromosome 17, clone hRPK.1053_B_8, complete sequence
Nrml-004 AL109759.4 Human chromosome 14 DNA sequence BAC R-898B23 of library RPCI-11 from chromosome 14 of 
Homo sapiens (Human), complete sequence
Nrml-005 AK026823.1 Homo sapiens cDNA: FLJ23170 fis, clone LNG09984
Nrml-006 AC019335.5 Homo sapiens chromosome 8, clone RP11-453N18, complete sequence
Nrml-007 AL162252.17 Human DNA sequence from clone RP11-55J24 on chromosome 9, complete sequence
Nrml-008 AC016644.9 Homo sapiens chromosome 5 clone RP11-52M14, complete sequence
* PCa clones were selected from the subtracted cDNA library that represents mRNA species only present in circulating cells of PCa patients.
** Nrml clones were selected from the subtracted cDNA library that represents mRNA species absent in circulating cells of PCa patients but 
present in their counterparts in cancer-free healthy men.
Table 2: PCR primers and conditions for detecting levels of mRNA expression in circulating cells of healthy men and patients with 
PCa
Clone I.D. GenBank Accession No. PCR primers cycles
PCa-001 AC132068 5'-AGG AAT AAG TCA CAC CGT GGA-3' 5'-ACC TGT TGG GAC TAG ACG CAT-3' 20
nested 5'-TGG TCT GTA ACC CTT AGG AGA-3' 5'-TCT GCC CTT TGA GTC CAA GT-3' 25
Pca-002 AC019106 5'-AGG TCA GCA GAG ATG TCT GT-3' 5'-TAG TCC CCG AGA AAG AAT TA-3' 32
Nrml-001 AC004690 5'-TGA GCA GTT TCT TCA GCC TCA-3' 5'-TGA TAA GTC CAA CCC AAA GGC T-3' 20
nested 5'-TAT CTG GGT GAC ACT GGG AAA-3' 5'-AGA GAC CAG CGT AAT ATC CCT-3' 30
Nrml-002 AK095899 5'-AGG TAA AGG AAA CCC CAA CAT GCA-3' 5'-AAC CAA CGA GGT GGC CGA ATC TT-3' 35Molecular Cancer 2005, 4:30 http://www.molecular-cancer.com/content/4/1/30
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Confirmation of differential gene expression in circulating cells of healthy men and PCa patients using semi-quantitative RT- PCR Figure 2
Confirmation of differential gene expression in circulating cells of healthy men and PCa patients using semi-
quantitative RT-PCR. RT-PCR was performed on individual samples from 8 healthy controls and 12 PCa patients to confirm 
the SSH results. After sequencing reaction to reveal the identities of a total of 23 clones present in the subtracted libraries, 
PCR primers were designed (Table 2). β-actin was also amplified from the same samples using a β-actin primer set (BD Bio-
scinces Clontech) to serve as an internal control for standardizing the quantity of the RNA applied in each reaction. After PCR 
amplification, aliquots (10 µl) of these PCR products were electrophoresed into 2% agarose gels followed by ethidium bromide 
staining.
Nrml-001
Nrml-002
PCa-001
PCa-002
β-actin
1 2 34 5678 123 4567891 0 1 1 1 2
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sequencing results (Table 2) and the designed primers
were subjected to a BLAST search to ensure that these
sequences do not match any identified mRNA with high
homology. As expected, PCa-001 and PCa-002 were
expressed at significantly higher levels in circulating cells
obtained from PCa patients than in healthy men (Figure
2). The detection of low levels of PCa-001 and PCa-002
may due to high sensitivity of RT-PCR-based detection.
Martin et al. also reported low levels of Mdm-2 and Gro-
alpha expression in peripheral blood mononuclear cells
of healthy samples using RT-PCR, whereas array-based
analysis did not show a detectible signal for these two
genes [31]. It is also possible that a very small number of
epithelial cells can be present in the peripheral blood of
healthy men [32] and PCa-001 and PCa-002 are epithelial
cells markers. Another two genes, Nrml-001 and Nrml-
002, were selected as absent in PCa patients' circulating
cells. These two genes were expressed, as expected, at
higher levels in healthy men than in PCa patients (Figure
2). β-actin has been shown to be constantly expressed in
Relative levels of target genes expression in peripheral blood circulating cells of healthy men and PCa patients Figure 3
Relative levels of target genes expression in peripheral blood circulating cells of healthy men and PCa patients. 
Images obtained from Figure 2 were captured and analyzed using the Quantity One® software. For each target gene, levels of 
gene expression were normalized to the level of β-actin expression for each individual sample. * indicates statistical significance 
between healthy men and PCa patients at p < 0.05.
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leukocytes of different individuals [33]. We also demon-
strated that level β-actin expression is similar in all our
samples (Figure 2). The relative levels of PCa-001, PCa-
002, Nrml-001, and Nrml-002 expression were then nor-
malized to β-actin and illustrated in Figure 3. Levels of
these genes' expression were statistically different between
healthy men and PCa patients.
In order to ensure that the PCR products were not resulted
from genomic DNA contamination, we performed two
pre-cautionary procedures. First, all total RNA samples
were subjected to RNase-free, DNase I digestion to remove
residual genomic DNA. Second, we noticed that, in reac-
tions with reverse transcription, β-actin signal was
detected after 26 cycles of PCR amplification (Figure 2),
whereas β-actin signal was absent in reactions without
reverse transcription even after 35 cycles of amplification
using amplimers within the same exon (data not shown).
However, before we can confirm our statement, full-
length cDNAs corresponding to our identified sequences
need to be cloned.
The genome-wide screening and identification of mRNA
species associated with circulating cells of tumor-bearing
patients has been described for various cancers. Twine et
al. reported the use of the microarray approach to differ-
entiate gene expression patterns of mononuclear cells in
patients with advanced renal cell carcinoma [34]. How-
ever, due to the low number of tumor cells present in the
circulation compared to the large number of normal leu-
kocytes, hybridization array (cDNA array and oligonucle-
otide array) may not be an ideal tool for identifying rare
molecular events occurring in small number of CTCs. To
overcome this problem, Smirnov et al. used magnetic sep-
aration of epithelial cell adhesion molecule (EpCAM)
expressing cells from peripheral blood circulating cells
and compared gene expression patterns between EpCAM-
enriched and EpCAM-depleted cells using microarray
analysis in cancer-bearing patients [35]. Another compre-
hensive gene expression method, named mRNA differen-
tial display, has been conducted to compare genes that are
expressed in peripheral blood mononuclear cells of
tumor-free individuals with those from lung, breast, and
colon cancer patients [36]. This study found a total of 21
mRNA species expressed in tumor patients' blood samples
but not in samples from tumor free volunteers. In addi-
tion, Martin et al. reported the use of the differential dis-
play to first identify transcripts differentially expressed in
breast cancer cells and normal breast epithelial cells fol-
lowed by an array analysis of these transcripts in the circu-
lating cells of breast cancer patients [31]. Results from
these experiments demonstrate that the detection of dis-
seminated cancer cells in peripheral blood is attainable.
It has been suggested that selective enrichment of the
tumor cell population from both bone marrow and blood
before analysis can increase the sensitivity for detecting
CTCs [37-40]. Various cell separation techniques have
been devised to enrich the CTC population from whole
blood. However, these methods may also introduce arti-
facts into the sample preparation steps. For example, the
addition of anticoagulants to blood samples affect leuko-
cyte gene expression ex vivo [41-43]. Efforts were made to
avoid RNA degradation and alteration in gene expression
during  in vitro processing of blood cells and to avoid
under- and over-estimation of in vivo mRNA expression.
We used direct isolation of poly(A)+ RNA and total RNA
from whole blood circumventing a prior cell separation
step. Our intention was also to prevent the loss of rare, un-
identified target cells from blood samples during enrich-
ment procedures since we do not know much about
tumor cells' genotypes/phenotypes or any type(s) of
immune cells' participation in cancer development.
Although it has been suggested that cancers are composed
of a heterogeneous collection of cells with different
degrees of tumor marker expressions [44,45], CTCs of all
types might need to develop a "common" mechanism(s)
to survive in the circulation and acquire metastatic capa-
bility. We speculate that universal "tumor-specific" mark-
ers can be identified in occult tumor cells from different
cancers. Moreover, we expect to identify "tissue-specific"
molecules in CTCs if tumor cells continue to express their
tissue-specific markers. The identification of tissue-spe-
cific markers will help to identify the origins of CTCs.
Emerging evidence also demonstrates that detection of
tumor cells disseminated in peripheral blood can provide
clinically important data for tumor staging, prognostica-
tion, and identification of surrogate markers for early
assessment of the effectiveness of adjuvant therapy.
Furthermore, by comparing gene expression profiling of
all circulating cells, we expect to identify genes that might
play a role in "immunosurveillance". Our future objec-
tives include the identification of cell types that expressed
differentially regulated mRNA species. We also intend to
study the functional activities of these molecules in circu-
lating cells during cancer development and establish an
association between these genes' expression and cancer
stages.
Conclusion
Using the PCR-based SSH technique, we established two
comprehensive subtracted cDNA libraries consisting of
potentially differentially regulated genes in circulating
cells of PCa patients. We further confirmed that both
elevated and suppressed transcripts can be detected in cir-
culating cells of PCa patients. This is an initial attempt to
perform genome-wide gene expression analysis in periph-
eral blood circulating cells and demonstrate the presenceMolecular Cancer 2005, 4:30 http://www.molecular-cancer.com/content/4/1/30
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of previously un-identified mRNA species in circulating
cells of cancer-bearing patients. This is the first step
toward understanding tumor metastasis and tumor-
induced immune reactions in the development of cancer.
We will continue to investigate these molecules' physio-
logical/pathological function and their use in cancer
detection.
Methods
Patient selection
PCa patients were enrolled at the time of diagnosis of ele-
vated PSA and positive biopsy. Healthy men's samples
were collected from volunteers with similar age and race
distribution without evidence of diseases or use of any
medications. Attending physicians provided all partici-
pants with informed consent forms for collecting samples
used in this study. Sample collection was also HIPAA
compliant. Blood was drawn before scheduled surgery
from PCa patients. There was no evidence of systemic
metastases for all PCa patients when the primary tumor
was resected through surgical prostatectomy. For initial
construction of SSH libraries, we collected 50 samples, 25
healthy men and 25 patients with PCa. We collected an
additional 20 blood samples, 8 healthy men and 12
patients with PCa, for RT-PCR analysis.
Blood collection and RNA isolation
For SSH, whole blood (5 ml) drawn from each individual
was immediately mixed with 10x volume of RNA stabili-
zation reagents for blood/bone marrow (Roche). The cells
were then lysed. Poly(A)+ RNA was immediately isolated
by a two-step procedure through magnetic separation
using the mRNA isolation kit for blood/bone marrow
(Roche). The poly(A)+  enriched samples were finally
eluted from magnetic beads with H2O. Purified poly(A)+
RNA was quantitated spectrophotometrically and stored
in liquid nitrogen until use.
For RT-PCR, blood (2.5 ml) from each individual was col-
leted into a PAXgene™ Blood RNA tube (QIAGEN) follow-
ing the manufacturer's protocol. Whole blood was
thoroughly mixed with PAXgene stabilization reagent and
stored at room temperature for 6 hours prior to RNA
extraction. Total RNA was then extracted using the PAX-
gene™ Blood RNA kit according to the manufacturer's
directions (QIAGEN). As the resulting RNA was usually
contaminated with genomic DNA [46], total RNA sam-
ples absorbed to the PAXgene™ Blood RNA System spin
column were incubated with DNase I (QIAGEN) at 25°C
for 20 min to remove genomic DNA. Total RNA was
eluted, quantitated, and stored in liquid nitrogen.
Suppression subtractive hybridization (SSH) procedures
SSH was performed according to procedures described by
Diatchenko et al. [25]. All reagents are now commercially
available from BD Biosciences Clontech. Briefly, reverse
transcription was performed with 2 µg poly(A)+ RNA from
an individual patient sample in the presence of a mixture
of three 3' anchored primers (5'-TTTGCATGCTCGAG-
(T)25-A/G/C-3') at 42°C for 2 hours. Second strand cDNA
was then synthesized with the addition of E. coli DNA
polymerase I (250 µU/µl; Invitrogen), E. coli RNase H (8.5
µU/µl; Invitrogen), and E. coli DNA ligase (30 µU/µl;
Invitrogen) at 16°C for an additional 2 hours. The dou-
ble-stranded cDNA libraries were then pooled into
healthy and PCa groups. The pooled samples were sub-
jected to Rsa  I digestion. To identify mRNA species
expressed only in patients with PCa, the Rsa I digested
pooled cDNAs derived from PCa were ligated to specially
designed adapters A and B (BD Biosciences Clontech) in
two different reactions [25].
To form heterohybrids between two sample populations,
the adapter A and adaptor B ligated cDNAs (20 ng) were
combined with excess Rsa I digested cDNAs (400 ng) from
healthy men in two separate reactions, heat-denatured,
and hybridized at 68°C for 10 hours. In a second hybrid-
ization step, the two separate samples from adapters A
and B containing reactions were combined. A fresh aliq-
uot of 150 ng heat-denatured Rsa  I digested cDNAs
derived from healthy men was added to the combined
reaction. Hybridization was continued for another 10
hours at 68°C. Commonly expressed sequences between
controls and PCa patients formed hybrids in these two
sequential hybridization steps. The heterohybrids are less
likely to be amplified in the following PCR step due to the
design of SSH adaptors [25].
Genes specifically expressed in PCa patients' circulating
cells were amplified by two consecutive rounds of PCR
according to the procedures reported by Diatchenko et al.
[25]. The PCR-amplified products were then ligated to the
pCRII vector (Invitrogen) followed by transformation.
The bacteria were plated on agar plates containing ampi-
cillin and overlaid with X-gal and IPTG. After overnight
incubation, white colonies were picked and used for sub-
sequent sequencing reaction. Sequencing results were
used to design PCR primer sets to determine the genes'
expression levels in healthy controls and PCa patients.
To detect sequences present in circulating cells of healthy
men but absent in circulating cells of PCa patients, the ini-
tial adaptors ligation reaction was reversed. Aliquots of
Rsa I digested pooled cDNAs derived from healthy men
were ligated to adapters A or B followed by hybridization
and PCR amplification as described above.
RT-PCR confirmation
First strand cDNAs were reverse transcribed from 2.5 µg of
the total RNA in the presence of oligo d(T) primer (Invit-Molecular Cancer 2005, 4:30 http://www.molecular-cancer.com/content/4/1/30
Page 9 of 10
(page number not for citation purposes)
rogen), 20 µM each of dNTPs, and 200 units of M-MLV
reverse transcriptase (Invitrogen). This was done in a total
of 50 µl at 42°C for 2 hours. PCR reactions were per-
formed by mixing 1 µl of first-strand cDNAs, 0.2 µM gene-
specific 5' and 3' primers (Table 2), and 5 units Taq DNA
polymerase (Invitrogen) in a total of 50 µl. Reactions were
performed by heat activation at 94°C for 2 min, followed
by cycling through 94°C for 30 sec, 50–55°C for 1 min,
and 72°C for 1 min. The minimal numbers of PCR cycles
required for detecting these gene products were first deter-
mined and is indicated in Table 2. β-actin (NM_001101)
was also amplified and used as an internal control for
comparing relative levels of target gene expression. We
also included RNA samples without reverse transcription
for β-actin amplification to determine levels of genomic
DNA contamination. Following gel electrophoresis,
images were captured using a Bio-Rad Gel Doc system;
and band intensities were analyzed by the Quantity One®
software (Bio-Rad).
Statistical Analysis
Levels of target gene expression were expressed as mean ±
standard deviation (SD) following normalization to β-
actin. A Student's t test was used to compare means of
these genes expressions between the healthy controls and
PCa patients. A probability value of p < 0.05 was consid-
ered significant.
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